Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Canadian Active & Maintenance Modified Pentasa Study (CAMMP)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Ferring Pharmaceuticals
ClinicalTrials.gov Identifier:
NCT00603733
First received: January 16, 2008
Last updated: April 21, 2016
Last verified: April 2016
Results First Received: March 4, 2015  
Study Type: Interventional
Study Design: Allocation: Randomized;   Endpoint Classification: Safety/Efficacy Study;   Intervention Model: Parallel Assignment;   Masking: Double Blind (Subject, Investigator);   Primary Purpose: Treatment
Conditions: Active Ulcerative Colitis
Remission of Ulcerative Colitis
Intervention: Drug: 5-ASA (5-Aminosalicylate)

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations

Total number of unique patients enrolled in the study is 288 whereby 190 patients were enrolled in the Active Phase and 98 patients were enrolled in the Run-In Phase.

The patients enrolled in the Maintenance Phase are a combination of patients who completed the Active (82) and Run In (71) Phases and were eligible to move forward into Maintenance.


Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
Pentasa® Modified Extended Release

5-ASA (5-Aminosalicylate)

5-ASA (5-Aminosalicylate): 500 mg tablet (modified extended release)

Pentasa®

5-ASA (5-Aminosalicylate)

5-ASA (5-Aminosalicylate): 500 mg tablet


Participant Flow for 3 periods

Period 1:   Active Phase ITT
    Pentasa® Modified Extended Release   Pentasa®
STARTED   95 [1]   95 
COMPLETED   84   78 
NOT COMPLETED   11   17 
Adverse Event                8                7 
Withdrawal by Subject                0                3 
Lost to Follow-up                0                1 
Did not meet inclusion/exclusion                1                3 
Lack of Efficacy                1                2 
Subject moved, site closed                1                1 
[1] Note: a total of 190 new participants were enrolled and randomized in the Active Phase

Period 2:   Run-In Phase - 4 Weeks
    Pentasa® Modified Extended Release   Pentasa®
STARTED   49 [1]   49 
COMPLETED   35   36 
NOT COMPLETED   14   13 
Adverse Event                2                1 
Withdrawal by Subject                4                1 
Lost to Follow-up                1                0 
Did not meet incl/excl criteria                5                10 
Lack of Efficacy                2                1 
[1] Note: Of the 98 subjects randomized at Run-In, 71 progressed into the maintenance phase.

Period 3:   Maintenance Phase ITT
    Pentasa® Modified Extended Release   Pentasa®
STARTED   71 [1]   82 
COMPLETED   61   66 
NOT COMPLETED   10   16 
Adverse Event                3                6 
Withdrawal by Subject                1                0 
Protocol Violation                1                1 
Lost to Follow-up                0                1 
Lack of Efficacy                2                2 
Physician Decision                0                1 
Site withdrew, subject away, lost IMP                3                5 
[1] Note:82 subjects randomized at Active phase & 71 at Run-In phase progressed to the maintenance phase



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
Baseline characteristics were reported for the Per Protocol population who participated in the Active phase and in the maintenance phase of this study.

Reporting Groups
  Description
Pentasa® Modified Extended Release

5-ASA (5-Aminosalicylate)

5-ASA (5-Aminosalicylate): 500 mg tablet (modified extended release)

Pentasa®

5-ASA (5-Aminosalicylate)

5-ASA (5-Aminosalicylate): 500 mg tablet

Total Total of all reporting groups

Baseline Measures
   Pentasa® Modified Extended Release   Pentasa®   Total 
Overall Participants Analyzed 
[Units: Participants]
 139   146   285 
Age 
[Units: Years]
Mean (Standard Deviation)
     
Active Phase   44.2  (12.88)   44.5  (12.53)   44.35  (12.71) 
Maintenance Phase   46.4  (12.20)   45.8  (13.45)   46.1  (12.83) 
Age, Customized 
[Units: Years]
Median (Full Range)
     
Active Phase   45 
 (18 to 68) 
 43.5 
 (22 to 76) 
 44.3 
 (18 to 76) 
Maintenance Phase   48 
 (20 to 65) 
 44.5 
 (23 to 76) 
 46.3 
 (20 to 76) 
Gender, Customized 
[Units: Participants]
     
Active Phase, Female   30   34   64 
Active Phase, Male   48   44   92 
Maintenance Phase, Female   28   29   57 
Maintenance Phase, Male   33   39   72 
Region of Enrollment 
[Units: Participants]
     
Canada   139   146   285 


  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Active Phase: Proportion of Active Subjects Achieving Overall Improvement   [ Time Frame: From baseline to week 8 ]

2.  Primary:   Maintenance Phase: Proportion of Subjects Experiencing Relapse   [ Time Frame: Up to week 24 ]

3.  Secondary:   Frequency of Adverse Events   [ Time Frame: From baseline to week 24 ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
Study was amended to modify sample size as subject enrolment was lower than anticipated. A data lock was imposed, pending completion of the Maintenance Phase by 12 subjects to report all Active Phase efficacy data & all available safety data.


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
The agreement is:
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.


Results Point of Contact:  
Name/Title: Clinical Development Support
Organization: Ferring Pharmaceuticals
e-mail: DK0-Disclosure@ferring.com



Responsible Party: Ferring Pharmaceuticals
ClinicalTrials.gov Identifier: NCT00603733     History of Changes
Other Study ID Numbers: CLN 35.3.11
Study First Received: January 16, 2008
Results First Received: March 4, 2015
Last Updated: April 21, 2016
Health Authority: Canada: Health Canada